Processa Pharmaceuticals Inc (PCSA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.93 (+1.58%), Market cap $0.01B, 52-week low–high $0.17 ~ $6.68.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinot
Financial statements, price targets, institutional (13F) holdings and related news for Processa Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Processa Pharmaceuticals Inc trades at $1.93 (+1.58%). Real-time quotes and charts are available on BlackAll Trade.
Processa Pharmaceuticals Inc has a market cap of about $0.01B.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's dru